Treatment of adult acute lymphoblastic leukemia—a therapeutic revolution in the making

Blood Cancer Journal · Published 2026-08-05 · DOI 10.1038/s41408-026-01583-y

Free full text

Authors (2)

Hagop Kantarjian, Ayalew Tefferi

Abstract

DOAJ holds no abstract for this record.

Read the article at the publisher →

Publication details

Year

2026

Citation

Kantarjian, H., Tefferi, A. (2026). Treatment of adult acute lymphoblastic leukemia—a therapeutic revolution in the making. Blood Cancer Journal. https://doi.org/10.1038/s41408-026-01583-y

Related articles

• Olverembatinib plus immunotherapy versus olverembatinib plus allogeneic hematopoietic cell transplantation in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia · Blood Cancer Journal · 2026 · Cites or is cited by this article · Same journal
• A Case Report of Tyrosine Kinase Inhibitor Interruption in a Patient with Multilineage Philadelphia-Positive Acute Lymphoblastic Leukemia · Acta Haematologica · 2026 · Cites or is cited by this article
• Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial · Leukemia · 2026 · Cites or is cited by this article
• Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients · Blood Cancer Journal · 2026 · Same journal
• Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma · Blood Cancer Journal · 2026 · Same journal
• Fixed-dose inotuzumab ozogamicin (INO) combined with Vincristine and Prednisone (VP) regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia (B-ALL): a multi-center, open-label, single-arm, prospective clinical study · Blood Cancer Journal · 2026 · Same journal
• Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study · Blood Cancer Journal · 2026 · Same journal
• Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial · Blood Cancer Journal · 2026 · Same journal
• Preclinical and clinical efficacy of the HDAC6 inhibitor ricolinostat in combination with BCR pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia · Blood Cancer Journal · 2026 · Same journal
• Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine · Blood Cancer Journal · 2026 · Same journal